Chulhee Choi,
Professor and Chair, BioMedical Imaging Center,
Korea Advanced Institute of Science and Technology (KAIST), President, ILIAS Biologics Incorporated
Chulhee Choi is Professor of Department of Bio and Brain Engineering at KAIST in South Korea. In addition, he is a scientific founder and CEO of ILIAS Biologics Incorporated, a company dedicated for development of exosome-based novel therapeutics. His group has been studying cell signaling involved in cell death and proliferation in inflammatory conditions and various malignant cancers. Dr. Choi’s group has also focused on development of novel biomedical imaging tools such as dynamic ICG fluorescence imaging for deep tissue perfusion and novel optical technology using femtosecond ultrashort pulsed lasers for modulation of biological functions. Recently, his team has demonstrated that optogenetic engineering of exosome producing cells can be applied for intracellular delivery of bioactive proteins with therapeutic potentials. His group is now pursuing research and development for clinically available exosome-based therapeutics. He is a graduate of Yonsei University College of Medicine, where he received his MD and PhD.
|
|
Exosome-based Delivery of Therapeutic Proteins: Principles and ApplicationsTuesday, 10 September 2019 at 09:30  Add to Calendar ▼2019-09-09 08:45:002019-09-09 09:45:00Europe/LondonChairperson's Welcome and Introduction to the ConferenceCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.comOur group has recently developed an opto-genetically engineered exosome system, named ‘exosomes for protein loading via optically reversible protein–protein interaction” (EXPLOR) that can deliver soluble proteins into the cytosol of target cells via controlled, reversible protein–protein interactions (PPI). By integrating a reversible PPI module controlled by specific wavelength of light with the endogenous process of exosome biogenesis, cargo proteins of our interest can be loaded into the exosomes. Engineered exosomes were shown to significantly increase intracellular levels of cargo proteins and their function in the recipient cells in both a time- and dose-dependent manner. In this presentation, I will introduce the basic principles of EXPLOR technology and follow-up studies for therapeutic applications focusing on novel anti-inflammatory exosomes in various disease models.
|
